Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Angela Fitch, the president of the Obesity Medicine Association, said that because obesity is a disease, treatments should be covered just like they are for diabetes or cancer
All treatments require evaluation by a licensed provider.
Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
While GLP-1RAs can directly stimulate mTORC1 in some contexts, the net effect of the impaired mTOR signaling during sustained caloric deficit may favor catabolism [34]
US$ 25.65
US$ 24.04
US$ 24.46
US$ 20.89
US$ 29.44
US$ 20.60
US$ 23.74
US$ 28.17
